Opendata, web and dolomites

GOLIATH SIGNED

Beating Goliath: Generation Of NoveL, Integrated and Internationally Harmonised Approaches for Testing Metabolism Disrupting Compounds

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 GOLIATH project word cloud

Explore the words cloud of the GOLIATH project. It provides you a very rough idea of what is the project "GOLIATH" about.

guidelines    strategy    silico    optimise    outcomes    anthropogenic    pivotal    validated    omics    throughput    focussing    ultimately    ready    metabolism    diabetes    humans    outcome    exposures    comprised    life    first    reached    iata    international    proportions    span    predictive    adverse    urgent    adipocytes    hepatocytes    link    metabolic    mode    disruption    generate    lack    endocrine    induce    reduce    biology    endocrinology    oecd    collectively    ongoing    screening    internationally    disorders    sc1    chemical    regulatory    assays    toxicity    mdcs    pancreatic    incorporating    regulation    molecular    vitro    entire    toxicology    vivo    human    obesity    technologies    2018    translating    epidemiology    disrupt    world    cells    goliath    health    action    edcs    experts    chemicals    cellular    harmonised    worldwide    27    goliathan    myocytes    acceptance    liver    natural    aop    spectrum    fatty    bhc    validation    disrupting   

Project "GOLIATH" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITEIT UTRECHT 

Organization address
address: HEIDELBERGLAAN 8
city: UTRECHT
postcode: 3584 CS
website: www.uu.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 6˙761˙833 €
 EC max contribution 6˙761˙833 € (100%)
 Programme 1. H2020-EU.3.1.1. (Understanding health, wellbeing and disease)
 Code Call H2020-SC1-2018-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2023-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITEIT UTRECHT NL (UTRECHT) coordinator 1˙268˙269.00
2    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) participant 1˙077˙695.00
3    INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT FR (PARIS CEDEX 07) participant 798˙786.00
4    UNIVERSIDAD MIGUEL HERNANDEZ DE ELCHE ES (ELCHE) participant 672˙862.00
5    Department of Health UK (Leeds) participant 459˙104.00
6    KAROLINSKA INSTITUTET SE (STOCKHOLM) participant 402˙500.00
7    THE REGENTS OF THE UNIVERSITY OF CALIFORNIA US (OAKLAND CA) participant 339˙596.00
8    LINKOPINGS UNIVERSITET SE (LINKOPING) participant 338˙287.00
9    UMEA UNIVERSITET SE (UMEA) participant 303˙750.00
10    BRUNEL UNIVERSITY LONDON UK (UXBRIDGE) participant 261˙946.00
11    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) participant 248˙525.00
12    BIOPREDIC INTERNATIONAL SARL FR (SAINT GREGOIRE) participant 243˙750.00
13    VLAAMSE INSTELLING VOOR TECHNOLOGISCH ONDERZOEK N.V. BE (MOL) participant 137˙510.00
14    AGENCE NATIONALE DE LA SECURITE SANITAIRE DE L ALIMENTATION DE L ENVIRONNEMENT ET DU TRAVAIL FR (MAISONS ALFORT) participant 134˙250.00
15    HOFFMANN SEBASTIAN DE (PADERBORN) participant 75˙000.00

Map

 Project objective

GOLIATH addresses the work programme topic ‘SC1-BHC-27-2018: New testing and screening methods to identify endocrine disrupting chemicals (EDCs)’ by focussing on one of the most urgent regulatory needs, namely the lack of methods for testing EDCs that disrupt metabolism – chemicals collectively referred to as ‘metabolism disrupting chemicals’ (MDCs). MDCs are natural and anthropogenic chemicals that have the ability to promote metabolic changes that can ultimately result in obesity, diabetes and/or fatty liver in humans. GOLIATH will generate the world’s first integrated approach to testing and assessment (IATA) specifically tailored to MDCs. With a focus on the main cellular targets of metabolic disruption – hepatocytes, pancreatic endocrine cells, myocytes and adipocytes - GOLIATH will develop new methods and optimise existing methods that span the entire adverse outcome pathway (AOP) spectrum, using in silico predictive modelling and high throughput screening, (pre-)validated ready-to-use in vitro assays and optimised in vivo toxicity testing guidelines. GOLIATH will provide key information on the endocrine mode of action by which MDCs disrupt metabolic pathways and induce adverse effects on human health by incorporating multi-omics technologies, and translating results from in vitro and in vivo assays to adverse metabolic health outcomes in humans at real life exposures. Given the importance of international acceptance of the developed test methods for regulatory use, GOLIATH will link with ongoing initiatives of the OECD for test method (pre-)validation, IATA and AOP development. With a consortium comprised of world-leading experts in endocrinology, molecular biology, toxicology, epidemiology, test method development, validation and chemical regulation, GOLIATH will be pivotal in the development of an internationally harmonised strategy for testing MDCs, and help to reduce the worldwide rise in metabolic disorders that have reached ‘Goliathan’ proportions.

 Deliverables

List of deliverables.
Detailed review paper on state of the art on MDCs Documents, reports 2020-03-06 13:48:50
Website open to the general public Websites, patent fillings, videos etc. 2020-02-25 14:36:32

Take a look to the deliverables list in detail:  detailed list of GOLIATH deliverables.

 Publications

year authors and title journal last update
List of publications.
2019 Melanie Schneider, Jean-Luc Pons, William Bourguet, Gilles Labesse
Towards accurate high-throughput ligand affinity prediction by exploiting structural ensembles, docking metrics and ligand similarity
published pages: 160-168, ISSN: 1367-4803, DOI: 10.1093/bioinformatics/btz538
Bioinformatics 36/1 2020-02-25
2019 Melanie Schneider, Jean-Luc Pons, Gilles Labesse, William Bourguet
In Silico Predictions of Endocrine Disruptors Properties
published pages: 2709-2716, ISSN: 1945-7170, DOI: 10.1210/en.2019-00382
Endocrinology 160/11 2020-02-25

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GOLIATH" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GOLIATH" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.1.)

ENDpoiNTs (2019)

Novel Testing Strategies for Endocrine Disruptors in the Context of Developmental NeuroToxicity

Read More  

ESPACE (2020)

Human Cell Atlas of the Pancreas

Read More  

BIND (2020)

Brain Involvement iN Dystrophinopathies

Read More